Analysis of structure-activity relationships for the 'B-region' of N-(3-acyloxy-2-benzylpropyl)-N′-[4-(methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: Discovery of an N-hydroxythiourea analogue with potent analgesic activity

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 9, 2004, Pages 2291-2297

  Lee, Jeewoo ^a   Kang, Sang Uk ^a   Choi, Hyun Kyung ^a   Lee, Jiyoun ^a   Lim, Ju Ok ^a   Kil, Min Jung ^a   Jin, Mi Kyung ^a   Kim, Kang Pil ^a   Sung, Jong Hyuk ^a   Chung, Suk Jae ^a   Ha, Hee Jin ^b   Kim, Young Ho ^b   Pearce, Larry V ^c   Tran, Richard ^c   Lundberg, Daniel J ^c   Wang, Yun ^c   Toth, Attila ^c   Blumberg, Peter M ^c  

^a Seoul National University   (South Korea)

^b Digital Bio Technology Co   (South Korea)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Analgesic; Antagonist; TRPV1; Vanilloid receptor 1

Indexed keywords

THIOUREA DERIVATIVE; VANILLOID RECEPTOR;

ANALGESIC ACTIVITY; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHEMICAL REACTION; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FEMALE; NONHUMAN; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANALGESICS; RECEPTORS, DRUG; STRUCTURE-ACTIVITY RELATIONSHIP; THIOUREA;

EID: 11144355751     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.02.002     Document Type: Article

References (41)

1. Gunthorpe M.J., Benham C.D., Randall A., Davis J.B. Trends Pharmacol. Sci. 23:2002;183.
2. Montell C., Birnbaumer L., Flockerzi V. Cell. 108:2002;595.
3. Szallasi A., Blumberg P.M. Pharmacol. Rev. 51:1999;159.
4. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. Nature. 389:1997;816.
5. Hayes P., Meadows H.J., Gunthorpe M.J., Harries M.H., Duckworth D.M., Cairns W., Harrison D.C., Clarke C.E., Ellington K., Prinjha R.K., Barton A.J.L., Medhurst A.D., Smith G.D., Topp S., Murdock P., Sanger G.J., Terrett J., Jenkins O., Benham C.D., Randall A.D., Gloger I.S., Davis J.B. Pain. 88:2000;205.
6. Jordt S.-E., Julius D. Cell. 108:2002;421.
7. Savidge J., Davis C., Shah K., Colley S., Phillips E., Ranasinghe S., Winter J., Kotsonis P., Rang H., McIntyre P. Neuropharmacology. 43:2002;450.
8. Tominaga M., Caterina M.J., Malmberg A.B., Rosen T.A., Gilbert H., Skinner K., Raumann B.E., Basbaum A.I., Julius D. Neuron. 21:1998;531.
9. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. Nature. 389:1997;816.
10. Walpole C.S.J., Wrigglesworth R. Capsaicin in the Study of Pain. 1993;Academic, San Diego, CA. p 63.
11. Appendino G., Szallasi A. Life Sci. 60:1997;681.
12. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H.-H., Sorgard M., Di Marzo V., Julius D., Hogestatt E.D. Nature. 400:1999;452.
13. Hwang S.W., Cho H., Kwak J., Lee S.Y., Kang C.J., Jung J., Cho S., Min K.H., Suh Y.G., Kim D., Oh U. Proc. Natl. Acad. Sci. U.S.A. 97:2000;6155.
14. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petersen-Zeitz K.R., Koltzenburg M., Basbaum A.I., Julius D. Science. 288:2000;306.
15. Walpole C.S.J., Bevan S., Bovermann G., Boelsterli J.J., Breckenridge R., Davies J.W., Hughes G.A., James I., Oberer L., Winter J., Wrigglesworth R. J. Med. Chem. 37:1994;1942.
16. Dray A., Forbes C.A., Burgess G.M. Neurosci. Lett. 110:1990;52.
17. Chen I.J., Lo Y.C., Lo W.J., Yeh J.L., Wu B.N. Gen. Pharmacol. 29:1997;387.
18. Wahl P., Foged C., Tullin S., Thomsen C. Mol. Pharmacol. 59:2001;9.
19. Seabrook G.R., Sutton K.G., Jarolimek W., Hollingworth G.J., Teague S., Webb J., Clark N., Boyce S., Kerby J., Ali Z., Chou M., Middleton R., Kaczorowski G., Jones A.B. J. Pharmacol. Exp. Ther. 303:2002;1052.
20. Garcia-Martinez C., Humet M., Planells-Cases R., Gomis A., Caprini M., Viana F., De le Pena E., Sanchez-Baeza F., Carbonell T., De Felipe C., Perez-Paya E., Belmonte C., Messeguer A., Ferrer-Montiel A. Proc. Natl. Acad. Sci. U.S.A. 99:2002;2374.
21. Himmel H.M., Kiss T., Borvendeg S.J., Gillen C., Illes P. J. Pharmacol. Exp. Ther. 301:2003;981.
22. Rami H.K., Davis J.B., Davies C.H., Egerton J., Gunthorpe M.J., Hadley M.S., Jerman J.C., Randall A.D., Smart D., Smith G.D., Soffin E.M., Thompson S.M., Wyman P.A. Drugs Fut. 27(Suppl. A):2002;411.
23. PCT WO 03/014064.
24. Sun Q., Tafesse L., Islam K., Zhou X., Victory S.F., Zhang C., Hachicha M., Schmid L.A., Patel A., Rotshteyn Y., Valenzano K.J., Kyle D. J. Bioorg. Med. Chem. Lett. 13:2003;3611.
25. Valenzano K.J., Grant E.R., Wu G., Hachicha M., Schmid L., Tafesse L., Sun Q., Rotshteyn Y., Francis J., Limberis J., Malik S., Wittemore E.R., Hodges D. J. Pharmacol. Exp. Ther. 306:2003;377.
26. Pomonis J.D., Harrison J.E., Mark L., Bristol D.R., Valenzano K.J., Walker K. J. Pharmacol. Exp. Ther. 306:2003;387.
27. Appendino G., Harrison S., De Petrocellis L., Daddario N., Bianchi F., Moriello A.S., Trevisani M., Benvenuti F., Geppetti P., Di Marzo V. Br. J. Pharmacol. 139:2003;1417.
28. Park H.-G., Park M.-K., Choi J.-Y., Choi S.-H., Lee J., Suh Y.-G., Oh U., Lee J., Kim H.-D., Park Y.-H., Jeong Y.S., Choi J.K., Jew S.-S. Bioorg. Med. Chem. Lett. 13:2003;197.
29. Park H.-G., Park M.-K., Choi J.-Y., Choi S.-H., Lee J., Suh Y.-G., Oh U., Lee J., Kim H.-D., Park Y.-H., Jeong Y.-S., Choi J.-K., Jew S.-S. Bioorg. Med. Chem. Lett. 13:2003;601.
30. Yoon J., Choi H., Lee H.J., Ryu C.H., Park H.-G., Suh Y.-G., Oh U., Jeong Y.S., Choi J.K., Park Y.-H., Kim H.-D. Bioorg. Med. Chem. Lett. 13:2003;1549.
31. Lee J., Lee J., Kang M., Shin M.-Y., Kim J.-M., Kang S.-U., Lim J.-O., Choi H.-K., Suh Y.-G., Park H.-G., Oh U., Kim H.-D., Park Y.-H., Ha H.-J., Kim Y.-H., Toth A., Wang Y., Tran R., Pearce L.V., Lundberg D.J., Blumberg P.M. J. Med. Chem. 46:2003;3116.
32. Wang Y., Toth A., Tran R., Szabo T., Welter J.D., Blumberg P.M., Lee J., Kang S.-U., Lim J.-O., Lee J. Mol. Pharm. 64:2003;325.
33. Lee J., Lee J., Kim J., Kim S.Y., Chun M.W., Cho H., Hwang S.W., Oh U., Park Y.H., Marquez V.E., Beheshti M., Szabo T., Blumberg P.M. Bioorg. Med. Chem. 9:2001;19.
34. Rama Rao A.V., Gurjar M.K., Lakshmipathi P., Reddy M.M., Nagarajan M., Pal S., Sarma B.V.N.B.S., Tripathy N.K. Tetrahedron Lett. 38:1997;7433.
35. Lee J., Lee J., Szabo T., Gonzalez A.F., Welter J.D., Blumberg P.M. Bioorg. Med. Chem. 9:2001;1713.
36. Mitsuya M., Kobayashi K., Kawakamin K., Satoh A., Ogino Y., Kakikawa T., Ohtake N., Kimura T., Hirose H., Sato A., Numazawa T., Hasegawa T., Noguchi K., Mase T. J. Med. Chem. 43:2000;5017.
37. Gallacher G., Smith C.Z., Hawkes G.E. Biog. Amines. 11:1995;49.
38. 50 values represent the mean of at least three experiments. Levels of partial agonism are from one to four experiments.
39. Wang Y., Szabo T., Welter J.D., Toth A., Tran R., Lee J., Kang S.U., Lee Y.-S., Min K.H., Suh Y.-G., Park M.-K., Park H.-G., Park Y.-H., Kim H.-D., Oh U., Blumberg P.M., Lee J. (erratum published in Mol. Pharmacol. 2003, 63, 589) Mol. Pharmacol. 62:2002;947.
40. Experimental protocols involving animals in this study were reviewed by the Animal Care and Use Committee of Digital Biotech Co., according to the NIH guidelines (NIH publication number 85-23, revised 1985) of 'Principles of Laboratory Animal Care'.
41. Since 1 and 12 are structurally related, we have studied whether 1 may be generated after the systemic administration of 12. Thus, 5 mg/kg of 12 was administered intravenously to male Sprague-Dawley rats (250-280 g) and 0.25 mL of blood was collected at various times up to 120 min. Plasma was collected and an aliquot (0.15 mL) was deproteinated by the addition of 0.3 mL acetonitrile. An aliquot of the supernatant (0.35 mL) was evaporated to dryness under a stream of nitrogen and the residue was reconstituted by the addition of 0.1 mL of mobile phase (water/methanol/acetonitrile=20:40:40). An aliquot of the mixture was injected directly onto the LC-MS system. Although both 1 and 12 could be readily quantified by the LC-MS system, the concentration of 12, but not 1, was detected in the sample. Since we could not have detected any conversion of 12 into 1, we conclude that the action of 12 cannot be explained by its conversion to 1 in vivo.